CK
NVCR icon

Carnick & Kubik’s NovoCure NVCR Stock Holding History

Carnick & Kubik’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		$14K Buy
+1,000
New +$14.3K ﹤0.01% 820

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Carnick & Kubik's NVCR Position: Q1 2016 in Review

Carnick & Kubik opened a new position in NovoCure (NVCR) in Q1 2016: 1,000 shares worth $14K. The stake represents ﹤0.01% of the portfolio and ranks #820 among its holdings.

58 funds tracked by Wall St. Rank hold NVCR as of Q1 2016.

  • Carnick & Kubik held 1,000 shares of NovoCure worth $14K as of Q1 2016.
  • NovoCure was a new Carnick & Kubik position in Q1 2016.
  • NovoCure made up ﹤0.01% of Carnick & Kubik's portfolio in Q1 2016, its #820 holding.
  • 58 funds tracked by Wall St. Rank held NovoCure as of Q1 2016.

Based on Carnick & Kubik's 13F filing for Q1 2016, filed 12 May 2016.